Furthermore, the CheckMate-648 study (70)showed that both nivolumab plus chemotherapy and nivolumab plus ipilimumab significantly improved overall survival compared to chemotherapy alone in unresectable/metastatic ESCC, with consistent benefits regardless of PD-L1 status. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.